Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

6.675 -0.195 (-2.84%)
Streaming Delayed Price Updated: 2:21 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Biotech Investing: How PRVs Can Unlock Major Opportunities
Biotech Investing: How PRVs Can Unlock Major Opportunities 
Via News Direct
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
Via InvestorPlace
Topics Economy
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Analyst Ratings for Day One Biopharmaceutical
 
Via Benzinga
The Latest Analyst Ratings for Day One Biopharmaceutical
 
Via Benzinga
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Dow Up Over 340 Points As Stocks Snap Back
The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well. 
Via Talk Markets
Topics Stocks
Where Day One Biopharmaceutical Stands With Analysts
 
Via Benzinga
Analyst Ratings for Day One Biopharmaceutical
 
Via Benzinga
Why Day One Biopharmaceuticals Stock Is Trading Higher Premarket Today
 
Via Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
$3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
7 Analysts Have This to Say About Day One Biopharmaceutical
 
Via Benzinga
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
Why Shares of Day One Pharmaceuticals Are Up Monday
The clinical-stage biotech released early trial news regarding its lead therapy candidate. 
Via The Motley Fool
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!' 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Day One Biopharmaceuticals, ImmunoGen And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.